BRAF and metastatic melanoma: In humans, 15 patients with BRAF V600-mutated metastatic melanoma were studied in a clinical trial involving the BRAF inhibitor dabrafenib, trametinib, and pembrolizumab as triple-combination therapy which may benefit this subset of patients by increasing the frequency of long-lasting anti-tumour responses.